Federal Circuit agrees that Exela infringed Ofirmev patents

The US Court of Appeals for the Federal Circuit yesterday (March 23) upheld a district court's decision that pharmaceutical company Exela infringed two patents covering Cadence Pharmaceuticals’s injectable Ofirmev (acetaminophen), used for pain relief.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?

Federal Circuit agrees that Exela infringed Ofirmev patents

Editor's picks

Editor's picks

More features